Yeruusaalem, 18 Nofembar, 2025 (TPS-IL) — Shirkadda dawooyinka ee Israa’iil ee BioLineRx Ltd. ayaa helay ogolaansho patent Mareykan ah oo loogu talagalay GLIX1, daaweyn loo adeegsanayo kansarrada halkaas oo cytidine deaminase (CDA) aan si xad-dhaaf ah u muuqan – taasoo daboolaysa in ka badan 90% kansarrada. Patent-ka ayaa ilaalinaya GLIX1 ilaa sanadka 2040, iyadoo suurtagal ah kordhin shan sano ah.

Daaweynta GLIX1, oo markii hore loo sameeyay glioblastoma, ayaa galaysa tijaabooyin ugu horreeya oo dadka lagu sameeyo horraanta sanadka 2026, iyadoo daraasado horudhac ah ay ka socdaan noocyada kale ee kansarrada.